Novanta Inc. NOVT
This picture changes. Follow Novanta Inc. free — email when the signal or risk changes + a Sunday weekly brief.
Follow Novanta Inc. freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Full analysis: 2 Aug 2026
Latest news check: 6 Aug 2026
General analysis — not personal advice.
HOLD
7/10
Confidence
Existing position may be maintained at current valuation.
Strong order intake, earnings beat and raised full-year guidance are balanced by integration risks and moderate organic growth.
Market sentiment
7/10
↑
Trend: Improving
The market reacts positively to the strong organic growth and raised guidance following the Riverpoint acquisition.
Price context
The stock trades at 159.49 USD after a 14.8 % weekly gain, 5.4 % below the 52-week high, reflecting that the market has quickly priced in the improved outlook.
Risk assessment
4/10
Dilution:
Low
Profitable company with strong cash flow
Jurisdiction:
Low
Primary operations in USA and Europe
Execution:
Medium
Acquisition integration and organic growth
Recent changes
- Report issued 5 August showed stronger-than-expected results and raised full-year guidance, driving positive market sentiment.
The full analysis is open. Follow the company free for the full change history — and email next time the picture changes.
Show all changes (2) — follow the company freeAbout the company
Novanta supplies precision components and subsystems to OEM customers in medical technology, robotics and advanced industry. The company operates three segments: Precision Medicine & Manufacturing, Medical Solutions and Robotics & Automation. Operations are profitable with growth both organically and through acquisitions.
Sector:
Precision technology, medical technology and industrial automation
Type:
Industrial
Next report
5 Nov 2026
Q3
Catalysts
Nov 2026
Q3 report
High
Q4 2026
Riverpoint synergies
Medium
Horizon:
Bull case
Accelerating organic growth and immediate positive contribution from the Riverpoint acquisition strengthen recurring revenues.
Bear case
High valuation requires continued perfection and integration risks could pressure margins.
Sensitivity analysis
| Factor | If it weakens | If it strengthens |
|---|---|---|
| AI datacenter growth | Lower growth in AI applications → reduced order intake and weaker revenue growth. | Continued strong growth in AI applications → higher revenue and improved profitability. |
| Riverpoint Medical integration | Delayed or weak integration → lower contribution to earnings per share than expected. | Successful integration → increased recurring revenue and margin improvement. |
We monitor these factors. Follow the company to get email when any of them hit.
Signal rationale (informational)
Strong order intake, earnings beat and raised full-year guidance are balanced by integration risks and moderate organic growth.
Recent news
- Novanta published the Q2 report on 5 August with revenue of 265.8 million USD, adjusted EPS of 0.89 USD beating expectations, and raised full-year guidance to 1.13–1.14 billion USD in revenue.
Key figures
Revenue
Q2 2026
USD 266M
Revenue TTM
TTM
USD 965M
EBITDA
Q2 2026
USD 60.7M
Net income
Q2 2026
USD 12.5M
Cash
2026-04-03
USD 389M
Total debt
Q1 2026
USD 249M
Gross margin
Q1 2026
44.9%
Shares outstanding
2026-06-15
37.8M
EPS
Q2 2026
USD 0.33
Price & valuation
Last close
USD 164
Market Cap
USD 6.2B
1 week
+7.0 %
3 months
+5.4 %
12 months
+35.2 %
From 52w high
-2.8 %
From 52w low
+65.1 %
Exchange
NASDAQ
Type
Industrials
Sector
Precision technology, medical technology and industrial automation
This picture changes. Follow Novanta Inc. free — email when the signal or risk changes + a Sunday weekly brief.
Follow 3 companies freeEmail when the signal or risk changes · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Firelda provides general information and analysis, not personal investment advice. Content does not consider your financial situation or goals. Investments can rise and fall in value. Always do your own research.